home / stock / ocgn / ocgn news

OCGN News and Press, Ocugen, Inc.

Stock Information
Company Name: Ocugen, Inc.
Stock Symbol: OCGN
Market: NASDAQ
Website: ocugen.com
Menu
OCGN OCGN Quote OCGN Short OCGN News OCGN Articles OCGN Message Board
Get OCGN Alerts

News, Short Squeeze, Breakout and More Instantly...
OCGN - Ocugen outlines 2026 BLA submission and expects three pivotal filings within three years amid leadership expansion

2026-03-04 13:33:06 ET More on Ocugen Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy ...
OCGN - Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript

2026-03-04 13:32:13 ET Ocugen, Inc. (OCGN) Q4 2025 Earnings Call March 4, 2026 8:30 AM EST Company Participants Tiffany Hamilton - AVP & Head of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Rita Johnson-Greene - Chief Financial Off...

OCGN - Ocugen (OCGN) Q4 2025 Earnings Call Transcript

2026-03-04 09:55:52 ET Image source: The Motley Fool. Wednesday, March 4, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

OCGN - Ocugen GAAP EPS of -$0.06 in-line

2026-03-04 08:17:32 ET More on Ocugen Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript Ocugen: Maintaining 'Buy' Rating On Positi...
OCGN - Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027. ...

OCGN - Expected US Company Earnings on Wednesday, March 4th, 2026

Riskified Ltd. Class A (RSKD) is expected to report $0.02 for Q4 2025 SunOpta Inc. (STKL) is expected to report $0.05 for Q4 2025 One Liberty Properties Inc. (OLP) is expected to report $0.41 for Q4 2025 Tourmaline Oil Corp (TRMLF) is expected to report $0.35 for Q4 2025 StubHub H...

OCGN - Ocugen Q4 2025 Earnings Preview

2026-03-03 11:00:09 ET More on Ocugen Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript Ocugen: Maintaining 'Buy' Rating On Positi...
OCGN - Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

2026-03-03 09:00:27 ET Next-generation cellular therapies and regenerative medicine drive exponential expansion New York, NY – March 3, 2026 – Market News Updates News Commentary – The global anti-aging therapy market is gaining serious momentum as peopl...

OCGN - Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patients Topline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 202...

OCGN - Earnings week ahead: AVGO, CRWD, PLUG, COST, TGT, MRVL, JD, KR, and more

2026-03-01 08:07:29 ET More on related stocks: Buy CrowdStrike As Trust Is Key In The Age Of AI Agents Costco's 2x P/E Over Amazon Is Not Irrational (Rating Upgrade) Broadcom Q1 Preview: Tech Rotation Could Trigger Another Irrational Selloff Costco is called ...
Next 10